Dori Pelled
Directeur des opérations chez Imel Biotherapeutics, Inc.
Profil
Dori Pelled is currently the Chief Operating Officer at Imel Biotherapeutics, Inc. He previously worked as the CTO & Director-Clinical Research at Enzymotec Ltd.
and as the Vice President-Operations at Eloxx Pharmaceuticals, Inc. He received his undergraduate and graduate degrees from Tel-Aviv University and his doctorate from Weizmann Institute of Science.
Postes actifs de Dori Pelled
| Sociétés | Poste | Début |
|---|---|---|
Imel Biotherapeutics, Inc.
 Imel Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Imel Biotherapeutics, Inc. develops treatment for mitochondrial disease. The company was founded on February 21, 2019 and is headquartered in United States. | Directeur des opérations | 01/03/2019 |
Anciens postes connus de Dori Pelled
| Sociétés | Poste | Fin |
|---|---|---|
| ELOXX PHARMACEUTICALS, INC. | Directeur des opérations | 25/06/2018 |
| ENZYMOTEC LTD. | Directeur Technique/Scientifique/R&D | - |
Formation de Dori Pelled
| Tel-Aviv University | Graduate Degree |
| Weizmann Institute of Science | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ELOXX PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Enzymotec Ltd.
 Enzymotec Ltd. BiotechnologyHealth Technology Enzymotec Ltd. develops and manufactures bio functional ingredients for health needs. The company was founded on March 8, 1998 and is headquartered in Migdal HaEmeq, Israel. | Health Technology |
Imel Biotherapeutics, Inc.
Imel Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Imel Biotherapeutics, Inc. develops treatment for mitochondrial disease. The company was founded on February 21, 2019 and is headquartered in United States. | Commercial Services |
